Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Random glucose GWAS in 493,036 individuals provides insights into diabetes pathophysiology, complications and treatment stratification
The study found that the rodents that had this knockout gene displayed increased levels of obesity, decreased libido, and an inability to copulate
Beta-alanine helps buffer lactic acid build-up, reducing muscle fatigue, while creatine supports ATP regeneration for sustained power output
The GLP-1 CVD outcome trials a) Elixa (Lexisenatide) b) Leader (Liraglutide) c) Sustain-6 (Semaglutide) d) Exscel (Weekly Exenatide) e) Harmony (Albiglutide) f) Rewind (Dulaglutide) g) Pioneer 6 (Oral Semaglutide) Elixa Study (Evaluation of Lixisenatide) In ELIXA, the investigational GLP-1 receptor agonist, lixisenatide, neither reduced nor increased cardiovascular events compared with placebo
Peptides and Their Relation to Proteins and Amino Acids: Amino acids are distinct chemical entities
It could improve cardiometabolic outcomes at scale in a country carrying one of the worlds largest burdens of obesity and type 2 diabetes
US$ 23.11
US$ 28.32
US$ 25.54
US$ 22.86
US$ 28.20
US$ 27.89
US$ 22.73
US$ 22.27
US$ 29.87
US$ 28.13
US$ 21.67
US$ 26.24
US$ 24.10
